Compare Royal Caribbean Cruises Ltd (RCL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Sanofi SA — how do they compare? Royal Caribbean Cruises Ltd trades at $260.05 (market cap $70.74B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| RCL | SNY | |
|---|---|---|
Market Cap | $70.74B | $104.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.23 | $52.34 |
52-Week Low | $246.71 | $41.33 |
Enterprise Value | $93.38B | $124.09B |
Dividend Yield | 2.27% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $264.5, down 0.26% on the day, with a bearish technical signal from moving averages but bullish oscillators. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $4.21 versus $3.98, and robust profitability margins including a 23.54% net income margin. Recent news highlights dividend declarations and institutional buying interest, though oil price increases pose near-term headwinds for cruise operators.
The outlook remains positive with analyst consensus price target of $367.83 implying significant upside, supported by earnings growth and debt reduction trends. Key risks include fuel cost volatility from rising oil prices and macroeconomic sensitivity, but institutional accumulation and strong cash flows provide a solid foundation for long-term investors.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
